10
play

10 TH ANNIVERSARY Summary report on CQDM economic impact - PowerPoint PPT Presentation

Oct 07, 2022 •235 likes •507 views

10 TH ANNIVERSARY Summary report on CQDM economic impact 2008-2018 Presented by : Diane Gosselin, CEO Novembre 2018 Founded in in 2008 by Vis isionaries Dawn Graham Max Fehlmann Alain Beaudet Paul Lvesque Bernard Prigent Philippe

  1. 10 TH ANNIVERSARY Summary report on CQDM economic impact 2008-2018 Presented by : Diane Gosselin, CEO Novembre 2018

  3. Founded in in 2008 by Vis isionaries Dawn Graham Max Fehlmann Alain Beaudet Paul Lévesque Bernard Prigent Philippe Walker 3

  4. A Uniq ique Coll llaborativ ive Model in in 2008 MISSION : ACCELERATE DRUG DISCOVERY AND DEVELOPMENT Pharma driven ◼ A collaborative ground between the private ◼ and academic sectors An emerging model in 2008 ◼ A lot of skepticism towards the CQDM model ◼ 4

  5. A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap PHARMA GOVERNMENTS CO-FUNDING PARTNERS 5

  6. A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap GOVERNMENTS CO-FUNDING PHARMA PARTNERS 6

  7. A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap GOVERNMENTS CO-FUNDING PARTNERS 7

  8. A Sig ignific icant Fin inancia ial Leverage to Fill ill the Gap HIGH-RISK, HIGH-REWARD PROJECTS ◼ Stimulate innovation by supporting early stage translational research ◼ Bridge academic research to the private sector ◼ Generate benefits for the academic and private sectors ◼ Address critical needs of the bio-pharmaceutical research 8

  9. A Survey to Measure the Im Impact of CQDM AREAS COVERED Enabling technologies, products and services generated ◼ The survey reflects the point Impact on the creation and growth of SMEs OVERALL OBJECTIVE ◼ of view of the Additional funding for academic institutions and SMEs ◼ Scale the impact of funded Follow-on partnerships with the pharma industry INVESTIGATORS ◼ projects on the ecosystem Jobs and trainings ◼ Outreach ◼ SOURCE OF QUANTITATIVE AND QUALITATIVE INFORMATION Annual and quarterly reports from the projects ◼ The survey reflects In depth survey on 64 projects ◼ the point of view of the Over 100 people interviewed (investigators and entrepreneurs involved in the ◼ projects) INVESTIGATORS Under the leadership of Gilles Duruflé, Economist 9

  10. Searchin ing for Scie ientific Excellence, , In Innovation and Im Impact 10 $68M 64 1200 FUNDING PROGRAMS FUNDING PROJECTS RESEARCHERS 49 calls for proposals $44M CQDM 25 Qc only 165 academic labs 825 proposals reviewed $24M Co-funding 11 Qc & International 31 SMEs partners 16 Qc & others provinces 12 outside Qc 10

  11. A Number of Partnership ips Fostered STRATEGIC LEVERAGE: 165 31 ACADEMIC SMEs ◼ ACCELERATE INNOVATION LABS ◼ INCREASE OUTREACH ◼ STIMULATE COMPANY GROWTH 10 ◼ ENHANCE COMPETITIVENESS LEADING PHARMA 11

  12. 64 projects funded 500 products, services 88% success rate 47 completed and research tools deliverables achieved 5 terminated generated from CQDM during funding projects 12 active 12

  13. Dia iagnostics and Research Tools Develo loped 30 DIAGNOSTICS 11 17 2 Discovery Clinical validation Market 309 14 INSTRUMENTS RESARCH TOOLS 5 3 6 Discovery Prototype Market 100 68 55 Assays Animal models Cell lines 265 20 13 9 OTHER TOOLS Methods & Processes Softwares Databases 13

  14. Several Therapeutic ics Generated from Pla latforms Developed 131 THERAPEUTICS IN DEVELOPMENT Validated 56 105 21 2 2 1 PLATFORMS Used in Discovery Preclinical Phase I Phase II Phase III Drug discovery research/ Drug delivery Commercialized Drug screening 14

  15. The Medic icago Example Seasonal Influenza : Phase III VLPExpress New programs initiated Rotavirus: Phase I discovery platform Norovirus: preclinical CQDM funding Rotavirus 3 undisclosed Seasonal Norovirus influenza 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Pandemic Ebola influenza Publicly owned Privately owned Phase II Market cap: $80M Raised over $300M 65 employees in investment Manufacturing optimization Pandemic Influenza vaccine - Phase I 350 employees $245M Factory Investment (Quebec) 15

  16. More than $194M in in Follow-on In Investments for r the the de development of of CQDM-funded technologie ies SOURCE OF FUNDS PRIVATE COMPANIES Pharma SMEs INVESTORS PRIVATE FOUNDATIONS PUBLIC AGENCIES CONSORTIA $10M $20M $30M $40M $50M 16

  17. Jo Jobs and Trainings Supported CQDM-FUNDED PROJECTS FOLLOW-ON 520 FTEs x year supported 1200 (including 191 students trained) FTEs x year highly skilled resources A network of 1200 researchers (estimated) ( 136 mentors from global pharma) 17

  18. A Colla llaborative Approach that Generates Benefit its for SMEs 165 31 ◼ 6 Start-ups ACADEMIC SMEs ◼ Growth of 40 existing companies LABS ◼ 1 foreign company established in Quebec 10 LEADING PHARMA 18

  19. Benefits Generated for SMEs ACCES TO INNOVATION DEVELOPMENT OF NEW PRODUCTS INCREASED RESEARCH CAPACITY UNIQUE FUNDING FOR R&D PARTNERSHIPS WITH PHARMA FUND RAISING 0% 20% 40% 60% 80% 100% % positive responses among entrepreneurs interviewed 19

  20. Benefits Generated from the Phama SUPPORT OF CQDM FUNDED PROJECTS ◼ $14M initial funding ◼ 136 mentors from global Pharma 165 31 ◼ Market pull approach ACADEMIC SMEs LABS PARTNERS FOR THE FUTURE ◼ 71 follow-on interactions and 10 partnerships with 26 different Pharma LEADING ◼ $41M follow-on investments PHARMA 20

  21. A Very ry Im Impressiv ive Fin inancial Leverage 300 13.2x 250 200 $1 of Qc government $1 of Qc government Follow-on $M invested investments funding generates funding generates 150 $4.2 for R&D $13.2 total funding 4.2 .2x 100 Funding of CQDM projects 50 (64) QC GOV. 0 21

  22. Conclusion • A CATALYST TO THE CULTURE OF COLLABORATIVE INNOVATION IMPACT • TRANSFORMATIVE EFFECT GENERATED FROM FUNDING BEYOND • A MODEL THAT DELIVERS HIGH VALUE PRODUCTS AND SERVICES EXPECTATIONS • FILLS THE GAP TO FOSTER INNOVATION 22

  23. Breaking up the Silo ilos to Conquer the Future 23

  24. A D Dedic icated Team Diane Gosselin Michael Bridges Steven Xanthoudakis Mario Chevrette Marc Thibault Véronique Dugas Mathieu Perrée Rebeca Baca-Diaz Jennifer Saleeb Olivier Carter Naëla Janmamode 24

  25. A Rig igorous Scie ientific An Exp xperie ienced Board Advis isory Board Chairman Chairman Richard Fajzel , CEO, Exactis Innovation Daniel Hétu , Managing Director, Lumira Capital Members Members Jennifer Chan , VP, Policy and Communications, Merck Canada Karen Akinsanya , Chief Biomedical Scientist, Schrödinger Diane Gosselin , President and CEO, CQDM André Darveau , Vice Rector, Administration, Raphael Hofstein , President and CEO, MaRS Innovation Université Laval Ken Pastor, General Partner, CTI Capital Diane Gosselin , President and CEO, CQDM Louise Proulx, Chief Development Officer, Therillia Reid Jason Leonard, Senior VP, Corporate Jorge Puente , Managing Partner, Pleasanton Pharma Ventures Development, Potenza Therapeutics Rémi Quirion , Quebec Chief Scientist Mark Lim , Assistant Director of Global Public Uwe Schoenbeck, Senior VP & CSO, External R&D Innovation, Health Programs, American Society for Pfizer worldwide R&D Microbiology Ali Tehrani , Co-founder, President and CEO, Zymeworks Patrick J. Wier , Senior VP, In Vitro/In Vivo Translation Platform, GSK 25

  26. An Ext xtended Canadian and In International Partner Network 26

Recommend

More recommend